CANbridge Pharmaceuticals (HKG:1228) served a notice of termination of its exclusive UMass license agreement with the University of Massachusetts.
The company is also actively negotiating the terms to cancel its lease of the group's office and laboratory space in Boston under its downsizing plan, a Friday Hong Kong bourse filing said.
Under the UMass license agreement, the company obtained global rights to develop, manufacture, and commercialize a certain spinal muscular atrophy-treating gene therapy in Jan. 2023. The termination will take effect within 60 days from the notice date.
The biopharmaceutical company's shares closed nearly 4% lower on Friday.
Price (HKD): $0.24, Change: $-0.0090, Percent Change: -3.60%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.